Cryo-Cell International, Inc. (CCEL)
$
4.35
-0.09 (-2.07%)
Key metrics
Financial statements
Free cash flow per share
0.7017
Market cap
37.1 Million
Price to sales ratio
1.1585
Debt to equity
-0.5879
Current ratio
0.6001
Income quality
-36.5179
Average inventory
703.6 Thousand
ROE
0.0129
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Cryo-Cell International, Inc. is engaged in cellular processing and cryogenic storage, specializing in the collection and preservation of umbilical cord blood stem cells for family use. The company reported an income before tax of $2,804,121.00 showcasing its pre-tax profitability. With an EBITDA of $1,422,959.00 a key indicator of the company's operational profitability, it demonstrates solid financial performance. The operating income ratio stands at 0.11 reflecting the company's operational profitability margin, while the EBITDA ratio is 0.04 highlighting operational efficiency. Additionally, the gross profit ratio is 0.75 which indicates the efficiency of the company's production and sales operations. Cryo-Cell also offers cord tissue services that retain a segment of umbilical cord tissue, a vital source of mesenchymal stem cells used in regenerative medicine to address various conditions, such as heart and kidney diseases, ALS, wound healing, and autoimmune disorders. The company manufactures and sells the PrepaCyte CB processing system, sophisticated technology for processing umbilical cord blood stem cells, and maintains a storage capacity of approximately 500,000 cord blood and cord tissue stem cells globally. Cryo-Cell International markets its preservation services directly to expectant parents and collaborates closely with obstetricians, pediatricians, childbirth educators, certified nurse-midwives, and other healthcare professionals. Established in 1989, the company is headquartered in Oldsmar, Florida. In terms of stock performance, the stock is affordable at $4.85 making it suitable for budget-conscious investors. However, it has a low average trading volume of 16,081.00 indicating lower market activity. With a market capitalization of $35,037,239.00 the company is classified as a small-cap player and operates as a key player in the Medical - Care Facilities industry, contributing significantly to the overall market landscape. Furthermore, it belongs to the Healthcare sector, driving innovation and growth within its field.
Is Cryo-Cell International, Inc. (CCEL) a good investment?
Investing in Cryo-Cell International, Inc. (CCEL) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as C, with a Bullish outlook. Always conduct your own research before investing.
What is Cryo-Cell International, Inc. (CCEL)'s stock forecast?
Analysts predict Cryo-Cell International, Inc. stock to fluctuate between $4.09 (low) and $9.43 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Cryo-Cell International, Inc.'s market capitalization?
As of 2025-10-27, Cryo-Cell International, Inc.'s market cap is $35,037,239, based on 8,053,612 outstanding shares.
How does Cryo-Cell International, Inc. compare to competitors like Meta Platforms, Inc. Class A Common Stock?
Compared to Meta Platforms, Inc. Class A Common Stock, Cryo-Cell International, Inc. has a Lower Market-Cap, indicating a difference in performance.
Does Cryo-Cell International, Inc. pay dividends?
Cryo-Cell International, Inc. pays dividends. The current dividend yield is 8.25%, with a payout of $0.15 per share.
How can I buy Cryo-Cell International, Inc. (CCEL) stock?
To buy Cryo-Cell International, Inc. (CCEL) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for CCEL. Place an order (Market, Limit, etc.).
What is the best time to invest in Cryo-Cell International, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bullish trend based on economic conditions and company performance.
How did Cryo-Cell International, Inc. perform in the last earnings report?
Revenue: $31,986,106 | EPS: $0.05 | Growth: -104.39%.
Where can I find Cryo-Cell International, Inc.'s investor relations reports?
Visit https://www.cryo-cell.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Cryo-Cell International, Inc.?
You can explore historical data from here
What is the all-time high and low for Cryo-Cell International, Inc. stock?
All-time high: $14.16 (2021-09-02) | All-time low: $2.69 (2023-03-23).
What are the key trends affecting Cryo-Cell International, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
businesswire.com
12 days ago
OLDSMAR, Fla.--(BUSINESS WIRE)--Cryo-Cell International, Inc. (NYSE American LLC Symbol: CCEL) (the “Company”, “Cryo-Cell”), the world's first private cord blood bank to separate and store stem cells in 1992, announced results for the fiscal third quarter ended August 31, 2025. Financial Results Revenue Consolidated revenues for the third quarter of fiscal 2025 were $7.83 million compared to $8.07 million for the third quarter of fiscal 2024, a 3% decrease. Net Income The Company reported net i.
businesswire.com
2 months ago
OLDSMAR, Fla.--(BUSINESS WIRE)--Cryo-Cell International, Inc. (NYSE American LLC: CCEL) (the “Company”, “Cryo-Cell”), the world's first private cord blood bank to separate and store stem cells in 1992, announced that the Company will not declare a quarterly cash dividend for the third quarter of fiscal 2025. This decision reflects lower-than-expected profitability. Cryo-Cell may or may not reinstate a dividend in future periods, and any future decisions regarding dividend declarations will be b.
businesswire.com
3 months ago
OLDSMAR, Fla.--(BUSINESS WIRE)--Cryo-Cell International, Inc. (NYSE American LLC: CCEL) (the “Company”), the world's first private cord blood bank to separate and store stem cells in 1992, announced results for the fiscal second quarter ended May 31, 2025. Financial Results Revenue The revenues for the second quarter of fiscal 2025 were $7.9 million compared to $8.0 million for the second quarter of fiscal 2024, a 1% decrease. The revenues for the second quarter of fiscal 2025 consisted of $7.8.
businesswire.com
6 months ago
OLDSMAR, Fla.--(BUSINESS WIRE)--Cryo-Cell International, Inc. (NYSE American LLC Symbol: CCEL) (“Cryo-Cell”), the world's first private cord blood bank to separate and store stem cells in 1992, announced today that, as a result of the current economic environment and other capital allocation alternatives, its Board of Directors has approved the payment of a reduced, quarterly cash dividend of $0.15 per share of common stock to be paid to its shareholders of record as of the close of business on.
businesswire.com
8 months ago
OLDSMAR, Fla.--(BUSINESS WIRE)--Cryo-Cell International, Inc. (NYSE American LLC: CCEL) (the “Company”), the world's first private cord blood bank to separate and store stem cells in 1992, announced results for its fiscal year ended November 30, 2024. Financial Results Revenue Consolidated revenues for fiscal 2024 were $32.0 million compared to $31.3 million for fiscal 2023. The revenues for fiscal 2024 consisted of $31.6 million in processing and storage fee revenue, $68,000 in product revenue.
businesswire.com
9 months ago
OLDSMAR, Fla.--(BUSINESS WIRE)--Cryo-Cell International, Inc. (NYSE American LLC Symbol: CCEL) (“Cryo-Cell”), the world's first private cord blood bank to separate and store stem cells in 1992, announced today that its Board of Directors has approved the payment of a quarterly cash dividend of $0.25 per share of common stock to be paid to its shareholders of record as of the close of business on February 14, 2025. The dividend is expected to be paid on February 28, 2025. The Board of Directors.
businesswire.com
a year ago
OLDSMAR, Fla.--(BUSINESS WIRE)--Cryo-Cell International, Inc. (NYSE American LLC Symbol: CCEL) (the “Company”), the world's first private cord blood bank to separate and store stem cells in 1992, announced results for the fiscal third quarter ended August 31, 2024. Financial Results Revenue Consolidated revenues for the third quarter of fiscal 2024 were $8.07 million compared to $7.87 million for the third quarter of fiscal 2023. Net Income The Company reported net income for the three months e.
businesswire.com
2 years ago
OLDSMAR, Fla.--(BUSINESS WIRE)--Cryo-Cell International, Inc. (NYSE American LLC: CCEL ) (the “Company”), the world's first private cord blood bank to separate and store stem cells in 1992, announced results for the fiscal first quarter ended February 29, 2024. Financial Results Revenue The revenues for the first quarter of fiscal 2024 were $7.85 million compared to $7.82 million for the first quarter of fiscal 2023. The revenues for the first quarter of fiscal 2024 consisted of $7.81 million i.
businesswire.com
2 years ago
OLDSMAR, Fla.--(BUSINESS WIRE)--Cryo-Cell International, Inc. (NYSE American LLC Symbol: CCEL) (the “Company”), the world's first private cord blood bank to separate and store stem cells in 1992, announced results for the fiscal third quarter ended August 31, 2023. Financial Results Revenue Consolidated revenues for the third quarter of fiscal 2023 were $7.87 million compared to $7.68 million for the third quarter of fiscal 2022. The revenues for the third quarter of fiscal 2023 consisted of $7.
businesswire.com
2 years ago
OLDSMAR, Fla.--(BUSINESS WIRE)--Cryo-Cell International, Inc. (NYSE American LLC: CCEL) (the “Company”), the world's first private cord blood bank to separate and store stem cells in 1992, announced results for the fiscal second quarter ended May 31, 2023. Financial Results Revenue Consolidated revenues for the second quarter of fiscal 2023 were $7.77 million compared to $7.63 million for the second quarter of fiscal 2022, a 2% increase. The revenues for the second quarter of fiscal 2023 consis.
See all news
